In March 2017 NICE announced their intentions to introduce a budget impact test for technologies within the Technology Appraisal and Highly Specialised Technologies programmes. The test, implemented from 1st April 2017 will assess the financial impact of a technology over the first three years of its use in the NHS.
If in any of these three years the budget impact exceeds £20million, NHS England may engage in commercial discussions with the company, even if the product has been deemed cost-effective.
The Association of the British Pharmaceutical Industry (ABPI) has deemed these changes to be “inappropriate and unworkable” as they will delay patient access to treatments for very rare diseases. As a result, on 10th July 2017, the ABPI announced that it has applied for a judicial review of the changes.
The ABPI’s chief executive, Mike Thompson, said: “We hope that the government will reverse the changes and work with us to find a solution that works for everyone”
- To read more about this (BBC News), please click here.
- To read the ABPI press release, please click here.
- MAP BioPharma Online members can also read more about the new budget impact changes on the MAP BioPharma website.